Galera Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GRTX research report →
About the company
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic.
- CEO
- J. Mel Sorensen
- IPO
- 2019
- Employees
- 3
- HQ
- Malvern, PA, US
Price Chart
- Market Cap
- $6.98M
- P/E
- 0.06
- P/S
- 0.00
- P/B
- 1.81
- EV/EBITDA
- -0.26
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -210.64%
- ROIC
- -114.15%
- Revenue
- $0 · 0.00%
- Net Income
- $149.05M · 886.25%
- EPS
- $1.51 · 531.43%
- Op Income
- $-6,042,000
- FCF YoY
- 50.19%
- 52W High
- $0.15
- 52W Low
- $0.01
- 50D MA
- $0.10
- 200D MA
- $0.05
- Beta
- 2.60
- Avg Volume
- 313.99K
Get TickerSpark's AI analysis on GRTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 15, 26 | Emerald Bioventures, LLC | other | 20,813,818 |
| May 15, 26 | Emerald Bioventures, LLC | other | 20,813.819 |
| Apr 7, 26 | Emerald Bioventures, LLC | other | 0 |
| Apr 7, 26 | Emerald Bioventures, LLC | other | 20,813,818.6 |
| Apr 7, 26 | FRIEDMAN MICHAEL R. | other | 5,336,870 |
| Apr 7, 26 | FRIEDMAN MICHAEL R. | other | 5,336.87 |
| Apr 7, 26 | CHANG NANCY T | other | 1,180,611 |
| Apr 7, 26 | CHANG NANCY T | other | 1,180.611 |
| Nov 20, 25 | Sorensen Mel | sell | 70,000 |
| May 1, 25 | Sussman Joel F. | other | 2,000,000 |
Our GRTX coverage
Recent articles, reports, and earnings notes.
No research on GRTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GRTX report →Similar companies
Peers in the same neighborhood.